Bristol-Myers Squibb Management
Management criteria checks 3/4
Bristol-Myers Squibb's CEO ist Chris Boerner , ernannt in Nov 2023, hat eine Amtszeit von weniger als einem Jahr. Die jährliche Gesamtvergütung beträgt $6.88M , bestehend aus 15.5% Gehalt und 84.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.004% der Aktien des Unternehmens, im Wert von $4.22M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3 Jahre bzw. 4.1 Jahre.
Key information
Chris Boerner
Chief executive officer
US$8.5m
Total compensation
CEO salary percentage | 14.9% |
CEO tenure | less than a year |
CEO ownership | 0.005% |
Management average tenure | 2.3yrs |
Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)
Apr 02Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 21Bristol-Myers Squibb Is Not A Buy For Me
Mar 19Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield
Mar 07Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60
Mar 07We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative
Feb 20Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Feb 06Bristol-Myers Squibb: Massive Discount Spells Opportunity
Feb 04BMY: Might Be Approaching A Bottom In 2024
Jan 23Investors Aren't Entirely Convinced By Bristol-Myers Squibb Company's (NYSE:BMY) Earnings
Jan 16Bristol-Myers Squibb: I Went Looking For Value And Found A 4.63% Yield Also
Jan 10Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation
Dec 31Bristol-Myers Squibb (NYSE:BMY) Has Announced That It Will Be Increasing Its Dividend To $0.60
Dec 26Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now
Dec 19Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock
Dec 12Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.60
Dec 11Bristol-Myers Squibb: The Patent Expiry Challenge
Nov 23Bristol Myers Squibb: Bright Future Ahead
Nov 17Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet
Nov 08Bristol-Myers Squibb: Time To Get Greedy
Oct 21CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$8m | US$1m | US$8b |
Sep 30 2023 | n/a | n/a | US$8b |
Jun 30 2023 | n/a | n/a | US$8b |
Mar 31 2023 | n/a | n/a | US$7b |
Dec 31 2022 | US$7m | US$1m | US$6b |
Sep 30 2022 | n/a | n/a | US$7b |
Jun 30 2022 | n/a | n/a | US$7b |
Mar 31 2022 | n/a | n/a | US$6b |
Dec 31 2021 | US$7m | US$1m | US$7b |
Sep 30 2021 | n/a | n/a | -US$5b |
Jun 30 2021 | n/a | n/a | -US$5b |
Mar 31 2021 | n/a | n/a | -US$6b |
Dec 31 2020 | US$6m | US$953k | -US$9b |
Sep 30 2020 | n/a | n/a | -US$44m |
Jun 30 2020 | n/a | n/a | -US$563m |
Mar 31 2020 | n/a | n/a | US$954m |
Dec 31 2019 | US$6m | US$891k | US$3b |
Vergütung im Vergleich zum Markt: ChrisDie Gesamtvergütung ($USD6.88M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD12.14M).
Entschädigung vs. Einkommen: ChrisDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.
CEO
Chris Boerner (52 yo)
less than a year
Tenure
US$8,461,833
Compensation
Dr. Christopher S. Boerner, also known as Chris, Ph.D. served as Chief Operating Officer at Bristol-Myers Squibb Company since April 26, 2023 to 2023 and served as its Executive Vice President since April...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Chairman | less than a year | US$8.46m | 0.0050% $ 5.3m | |
Executive VP & CFO | 4.4yrs | US$7.17m | 0.0096% $ 10.2m | |
Executive VP & General Counsel | 17.2yrs | US$5.92m | 0.022% $ 23.4m | |
Executive VP | 4.8yrs | US$6.23m | 0.0030% $ 3.1m | |
Executive VP and Chief Digital & Technology Officer | 2.3yrs | no data | 0.00026% $ 275.0k | |
VP & Head of Investor Relations | no data | no data | no data | |
Chief Compliance & Ethics Officer | less than a year | no data | no data | |
Executive Vice President & Chief Human Resources Officer | less than a year | no data | 0.00013% $ 137.5k | |
Head of Medical Affairs | no data | no data | no data | |
Executive VP | no data | no data | 0.00080% $ 846.1k | |
Senior Vice President of Major Markets | no data | no data | no data | |
Executive Vice President of Global Product Development & Supply | 2.3yrs | no data | 0.00020% $ 211.5k |
2.3yrs
Average Tenure
53yo
Average Age
Erfahrenes Management: BMYDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Chairman | 1.3yrs | US$8.46m | 0.0050% $ 5.3m | |
Independent Director | 12.3yrs | US$357.50k | 0% $ 0 | |
Independent Director | 3.6yrs | US$375.00k | 0% $ 0 | |
Independent Director | 4.4yrs | US$365.00k | 0% $ 0 | |
Independent Director | 8yrs | US$359.68k | 0% $ 0 | |
Independent Director | 1.8yrs | US$329.97k | 0% $ 0 | |
Lead Independent Director | 7.2yrs | US$425.00k | 0.0018% $ 1.9m | |
Independent Director | 3.6yrs | US$365.00k | 0% $ 0 | |
Independent Director | 4.4yrs | US$371.68k | 0.00067% $ 708.6k | |
Independent Director | 6.3yrs | US$344.74k | 0% $ 0 | |
Independent Director | 2.8yrs | US$335.00k | 0% $ 0 |
4.4yrs
Average Tenure
62yo
Average Age
Erfahrener Vorstand: BMYDie Vorstandsmitglieder gelten als erfahren (4.1 Jahre durchschnittliche Amtszeit).